- Home
- Publications
- Publication Search
- Publication Details
Title
COVID-19 in teriflunomide-treated patients with multiple sclerosis
Authors
Keywords
-
Journal
JOURNAL OF NEUROLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-04
DOI
10.1007/s00415-020-09944-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Characteristics of Coronavirus Disease 2019 in China
- (2020) Wei-jie Guan et al. NEW ENGLAND JOURNAL OF MEDICINE
- COVID-19 infection: the perspectives on immune responses
- (2020) Yufang Shi et al. CELL DEATH AND DIFFERENTIATION
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- (2020) Fei Zhou et al. LANCET
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Covid-19: what treatments are being investigated?
- (2020) Elisabeth Mahase BMJ-British Medical Journal
- The COVID-19 pandemic and the use of MS disease-modifying therapies
- (2020) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
- (2020) Mahdi Barzegar et al. Neurology-Neuroimmunology & Neuroinflammation
- An Italian programme for COVID-19 infection in multiple sclerosis
- (2020) Maria Pia Sormani LANCET NEUROLOGY
- COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
- (2020) Giovanni Novi et al. Multiple Sclerosis and Related Disorders
- The prevalence of MS in the United States
- (2019) Mitchell T. Wallin et al. NEUROLOGY
- Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus
- (2019) Gong Mei-jiao et al. BIOMEDICINE & PHARMACOTHERAPY
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
- (2019) Gustavo Luna et al. JAMA Neurology
- A genome-wide siRNA screen identifies a druggable host pathway essential for the Ebola virus life cycle
- (2018) Scott Martin et al. Genome Medicine
- Treatment of Theiler’s virus-induced demyelinating disease with teriflunomide
- (2017) Francesca Gilli et al. JOURNAL OF NEUROVIROLOGY
- Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication
- (2017) Andrea Bilger et al. Oncotarget
- Aging of the immune system: Focus on inflammation and vaccination
- (2016) Marcello Pinti et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Critical Illness in Patients with Multiple Sclerosis: A Matched Case-Control Study
- (2016) Anush Karamyan et al. PLoS One
- Infection as an Environmental Trigger of Multiple Sclerosis Disease Exacerbation
- (2015) Andrew J. Steelman Frontiers in Immunology
- Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
- (2014) Amit Bar-Or et al. DRUGS
- Brain Atrophy in Radiologically Isolated Syndromes
- (2014) Juan Ignacio Rojas et al. JOURNAL OF NEUROIMAGING
- Teriflunomide for the treatment of multiple sclerosis
- (2013) Clemens Warnke et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Hospital admission due to infections in multiple sclerosis patients
- (2013) S. Montgomery et al. EUROPEAN JOURNAL OF NEUROLOGY
- Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab
- (2013) W. Kim et al. EUROPEAN JOURNAL OF NEUROLOGY
- Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis
- (2013) A. Bar-Or et al. NEUROLOGY
- Exacerbated Innate Host Response to SARS-CoV in Aged Non-Human Primates
- (2010) Saskia L. Smits et al. PLoS Pathogens
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More